ATE304011T1 - Hydantoin-enthaltende glucokinase aktivatoren - Google Patents

Hydantoin-enthaltende glucokinase aktivatoren

Info

Publication number
ATE304011T1
ATE304011T1 AT01925563T AT01925563T ATE304011T1 AT E304011 T1 ATE304011 T1 AT E304011T1 AT 01925563 T AT01925563 T AT 01925563T AT 01925563 T AT01925563 T AT 01925563T AT E304011 T1 ATE304011 T1 AT E304011T1
Authority
AT
Austria
Prior art keywords
glucocinase
activators
hydantoin containing
hydantoin
glucocinase activators
Prior art date
Application number
AT01925563T
Other languages
English (en)
Inventor
Robert Alan Goodnow Jr
Kang Le
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE304011T1 publication Critical patent/ATE304011T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01925563T 2000-05-03 2001-04-23 Hydantoin-enthaltende glucokinase aktivatoren ATE304011T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20149800P 2000-05-03 2000-05-03
PCT/EP2001/004555 WO2001083478A2 (en) 2000-05-03 2001-04-23 Hydantoin-containing glucokinase activators

Publications (1)

Publication Number Publication Date
ATE304011T1 true ATE304011T1 (de) 2005-09-15

Family

ID=22746054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925563T ATE304011T1 (de) 2000-05-03 2001-04-23 Hydantoin-enthaltende glucokinase aktivatoren

Country Status (20)

Country Link
US (2) US6583288B2 (de)
EP (1) EP1280801B1 (de)
JP (1) JP3842131B2 (de)
KR (1) KR100505312B1 (de)
CN (1) CN1209361C (de)
AR (1) AR034253A1 (de)
AT (1) ATE304011T1 (de)
AU (2) AU5227001A (de)
BR (1) BR0110492A (de)
CA (1) CA2407428C (de)
DE (1) DE60113247T2 (de)
DK (1) DK1280801T3 (de)
EC (1) ECSP014055A (de)
ES (1) ES2248309T3 (de)
MX (1) MXPA02010746A (de)
PE (1) PE20011313A1 (de)
PT (1) PT1280801E (de)
UY (1) UY26689A1 (de)
WO (1) WO2001083478A2 (de)
ZA (1) ZA200208370B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
KR101018318B1 (ko) 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Gk 활성제로서의 아미드 유도체
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
MX2007001846A (es) * 2004-08-17 2007-03-28 Hoffmann La Roche Hidantoinas sustituidas.
CA2579717A1 (en) * 2004-09-09 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US8003792B2 (en) 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー/エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
CN101312940B (zh) 2005-11-17 2012-11-14 伊莱利利公司 胰高血糖素受体拮抗剂、制备和治疗用途
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
FR2894962B1 (fr) * 2005-12-20 2008-03-14 Pharmamens Sarl Hydantoines a action insulinotropique
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
EP2001875A2 (de) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase-aktivatoren
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (de) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8034819B2 (en) * 2007-03-07 2011-10-11 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
JP2010521457A (ja) * 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムcgrp受容体アンタゴニスト
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
EP2188276B1 (de) * 2007-08-16 2012-03-28 F. Hoffmann-La Roche AG Substituierte hydantoine
CN101896469A (zh) 2007-12-20 2010-11-24 霍夫曼-拉罗奇有限公司 作为mek激酶抑制剂的取代的乙内酰脲类化合物
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
JP5513492B2 (ja) 2008-05-16 2014-06-04 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
EP2459554B1 (de) 2009-07-31 2013-09-18 Cadila Healthcare Limited Substituierte benzamidderivate als glucokinase (gk)-aktivatoren
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
ES2671881B1 (es) * 2016-11-11 2019-03-25 Consejo Superior Investigacion Procedimiento de obtencion de polimeros con grupos isocianato
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren

Also Published As

Publication number Publication date
EP1280801A2 (de) 2003-02-05
AU5227001A (en) 2001-11-12
CN1427838A (zh) 2003-07-02
BR0110492A (pt) 2003-04-08
CA2407428A1 (en) 2001-11-08
KR20020093120A (ko) 2002-12-12
JP3842131B2 (ja) 2006-11-08
WO2001083478A3 (en) 2002-05-16
UY26689A1 (es) 2001-11-30
MXPA02010746A (es) 2003-03-10
ECSP014055A (es) 2002-01-25
EP1280801B1 (de) 2005-09-07
DE60113247D1 (de) 2005-10-13
AR034253A1 (es) 2004-02-18
US6583288B2 (en) 2003-06-24
ES2248309T3 (es) 2006-03-16
CN1209361C (zh) 2005-07-06
US20010056191A1 (en) 2001-12-27
WO2001083478A2 (en) 2001-11-08
AU2001252270B2 (en) 2005-12-15
PT1280801E (pt) 2005-11-30
US6784298B2 (en) 2004-08-31
US20030225286A1 (en) 2003-12-04
CA2407428C (en) 2010-02-02
PE20011313A1 (es) 2001-12-28
ZA200208370B (en) 2004-01-26
JP2003531905A (ja) 2003-10-28
DK1280801T3 (da) 2006-01-23
KR100505312B1 (ko) 2005-08-04
DE60113247T2 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
DK1280801T3 (da) Hydantoinholdige glucokinaseaktivatorer
DK1169312T3 (da) Glucokinaseaktivatorer
DK1242397T3 (da) Trans-olefiniske glucokinaseaktivatorer
ATE297921T1 (de) Tetrazolylphenyl-acetamide als glukokinaseaktivatoren
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
NO20030472L (no) Imidazolderivater
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DE60131992D1 (de) Pfropfcopolymere enthaltende klebstoffe
DK1529530T5 (da) Glucokinase påvirkende forbindelser
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
ATE360620T1 (de) Imidazolderivate
ATE388040T1 (de) Träger
DE50009640D1 (de) Drehmaschine
DE50011953D1 (de) Bohrwerkzeug
NO20025659L (no) Heterocykliske forbindelser
DE50100739D1 (de) Drehmaschine
DE50011611D1 (de) Bohrwerkzeug
DE50113112D1 (de) Schaltungsanordnung
DE50102328D1 (de) Feuchttücher (i)
DE50110971D1 (de) Werkzeughalter
BR0107047B1 (pt) artigo absorvente.
FI20001260L (fi) Kontti
DE50104260D1 (de) Behälter
DE50115426D1 (de) Schaltungsanordnung
FI20000173L (fi) Nesteen syöttäminen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1280801

Country of ref document: EP

REN Ceased due to non-payment of the annual fee